CN104666550B - A kind of Chinese medicine composition for treating NASH - Google Patents
A kind of Chinese medicine composition for treating NASH Download PDFInfo
- Publication number
- CN104666550B CN104666550B CN201510147954.XA CN201510147954A CN104666550B CN 104666550 B CN104666550 B CN 104666550B CN 201510147954 A CN201510147954 A CN 201510147954A CN 104666550 B CN104666550 B CN 104666550B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- liver
- medicine composition
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of Chinese medicine composition for treating NASH, it is made up of the chinese medicine material or their extract of following parts by weight, 5~10 parts of 10~20 parts of tinosporae, 10~20 parts of golden cypress, 20~30 parts of sweet wormwood, 10~20 parts of stringy stonecrop, 20~30 parts of the Radix Astragali and semen armeniacae amarae.Said composition has the effect of spleen clearing damp, clearing heat and detoxicating, reducing blood lipid liver protection, and treatment non-alcoholic fatty liver is evident in efficacy.
Description
Technical field
The invention belongs to the field of Chinese medicines, and in particular to a kind of Chinese medicine composition for treating non-alcohol fatty liver.
Background technology
Non-alcohol fatty liver (Nonalcoholic fatty liver disease, NAFLD) refer to except wine
Essence and caused by other clearly damage liver factors, using diffusivity liver cell Macrovesicular steatosis to be principal character, common slow
One of property hepatopathy, serious harm people's health, and have and develop into liver fibrosis, the possibility of hepatic sclerosis, wherein with bright with liver
The nonalcoholic fatty liver disease (Nonalcoholic steatosisi hepatitis, NASH) of aobvious damage carries out diet, fortune
The lifestyle modification such as dynamic is its basis and crucial intervening measure.
Non-alcohol fatty liver (NAFLD) and fat and metabolic syndrome are closely related, there is no specific treatment medicine,
It is current maximally effective treatment method to be lost weight by dietary adjustments and motion.Dietetic treatment mainly includes standard of appraisal body
Weight, estimation heat, selection food, kinesiatrics are mainly made up of five Fundamentals, i.e. motion mode, exercise intensity, motion
Duration, exercise time-bands, the frequency implemented.
Traditional Chinese medicine prevention non-alcohol fatty liver (NAFLD) determined curative effect, there is Small side effects.
The content of the invention
It is an object of the invention to provide a kind of Chinese medicine composition for treating non-alcohol fatty liver, said composition tool
There are spleen clearing damp, clearing heat and detoxicating, reducing blood lipid liver protection, treatment non-alcoholic fatty liver is evident in efficacy.
The present invention a kind of Chinese medicine composition for treating NASH, by the chinese medicine material of following parts by weight or it
Extract composition, 10~20 parts of tinosporae, 10~20 parts of golden cypress, 20~30 parts of sweet wormwood, 10~20 parts of stringy stonecrop, the Radix Astragali 20
~30 parts and 5~10 parts of semen armeniacae amarae.
It is preferred that, the Chinese medicine composition for the treatment of NASH of the invention, by the chinese medicine material of following parts by weight
Or their extract composition, 16 parts of tinosporae, 15 parts of golden cypress, 25 parts of sweet wormwood, 15 parts of stringy stonecrop, 26 parts of the Radix Astragali and semen armeniacae amarae 8
Part.
In one embodiment, a kind of Chinese medicine composition for treating NASH of the invention, by following
The chinese medicine material of parts by weight or their extract composition, 10~20g of tinosporae, 10~20g of golden cypress, 20~30g of sweet wormwood, vertical basin
10~20g of grass, 5~10g of 20~30g of the Radix Astragali and semen armeniacae amarae.
In above-mentioned specific embodiment, it is preferred that Chinese medicine composition of the invention, by following weight chinese medicine material or
Their extract composition, tinosporae 16g, golden cypress 15g, sweet wormwood 25g, stringy stonecrop 15g, Radix Astragali 26g and semen armeniacae amarae 8g.
Pharmaceutical preparation, the extract and pharmaceutic adjuvant of the Chinese medicine composition containing the present invention, its dosage form is tablet, ball
Agent, particle, capsule or injection, the extract are to boil the medicinal material of the Chinese medicine composition of the present invention with decocting, separate decoction,
Be condensed into medicinal extract, or by extract dry, be ground into particle or powder.Medicinal extract, dry particle or powder are added into customary adjuvant
Tablet, capsule, granule pill is made, or capsule directly is made in particle loading capsule.
Said medicine preparation, can also remove decoction after colloid and coloring matter, sterilized that injection is made.
Pharmaceutical preparation described above, the pharmaceutic adjuvant includes filler, disintegrant, adhesive, lubricant, sweet, this
It is prepared by a little auxiliary materials all auxiliary materials commonly used in the art, the preparation method of the corresponding formulation of the preparation method of preparation also routinely.
Beneficial effects of the present invention：The Chinese medicine composition of the present invention has spleen clearing damp, clearing heat and detoxicating, reducing blood lipid liver protection work(
Effect, treatment non-alcoholic fatty liver curative effect is good, few side effects.
Embodiment
Following examples do not limit the scope of the present invention to understand the essence of the present invention with this, in the reality of the present invention
The lower increase and decrease carried out of matter spirit and change recipe quantity fall within the scope of the present invention.
Embodiment 1
Chinese medicine composition composition：
Tinosporae 16g, golden cypress 15g, sweet wormwood 25g, stringy stonecrop 15g, Radix Astragali 26g and semen armeniacae amarae 8g
Tinosporae, golden cypress, sweet wormwood, stringy stonecrop, the Radix Astragali and the semen armeniacae amarae of recipe quantity are taken, is put into stainless-steel pan, water is added,
Water at least flooded medicinal material face, and heating is decocted 30~50 minutes, isolates decoction, the dregs of a decoction add water, and water flooded medicinal material face,
Heating 30 minutes, isolates decoction, and step operation, isolates decoction before repeating, and merges decoction and decoction is made.The decoction takes in three times
With that is, three times per day.
Or medicine liquid heating is further condensed into medicinal extract, powdered extract is ground into particle, and particle is distributed into 6 glue
In capsule, capsule is made.Refilled after filler, mixing are added when necessary into capsule.Three times per day, once two grains.
Embodiment 2
Chinese medicine composition composition：
Tinosporae 10g, golden cypress 20g, sweet wormwood 20g, stringy stonecrop 10g, Radix Astragali 20g and semen armeniacae amarae 10g
Tinosporae, golden cypress, sweet wormwood, stringy stonecrop, the Radix Astragali and the semen armeniacae amarae of recipe quantity are taken, is put into stainless-steel pan, water is added,
Water at least flooded medicinal material face, and heating is decocted 30~50 minutes, isolates decoction, the dregs of a decoction add water, and water flooded medicinal material face,
Heating 30 minutes, isolates decoction, and step operation, isolates decoction before repeating, and merges decoction and decoction is made.Medicine liquid heating is concentrated
Into medicinal extract, powdered extract is ground into particle, and particle is distributed into 6 capsules, capsule is made.Add and fill out when necessary
Refilled after filling agent, mixing into capsule.Three times per day, once two grains.
Embodiment 3
Chinese medicine composition composition：
Tinosporae 20g, golden cypress 10g, sweet wormwood 30g, stringy stonecrop 20g, Radix Astragali 30g and semen armeniacae amarae 5g.By the technique of embodiment 2
It is prepared into capsule.
The clinical trial of embodiment 4
Enter a group case, 80 non-alcohol Patients with Fatty Liver, man 60, female 20.Age, average age was at 35~65 years old
46.1 years old.
Diagnostic criteria
According to Chinese Medical Association's hepatology branch fatty liver and AML group in revision in 2 months 2006《It is non-
The practice guidelines of alcohol fatty liver》.
Histodiagnosis
(1) non-alcoholic simple fatty liver：More than 30% hepatic cell fattydegeneration in low power lens downward view, but nothing
Other obvious Histological change, i.e. no inflammations, necrosis and fibrosis.The fatty change person of 30%~50% liver cell is light in the visual field
Fatty liver is spent, 50%~75% liver cell fat change person is moderate fatty liver, and more than 75% liver cell fat change person is severe fat
Fat liver.The liver cell ＜ that fat becomes in low power lens downward view is referred to as hepatic cell fattydegeneration.
(2) fat hepatitis：(1) liver cell is bullous or Combination steatosis based on bullous；(2) liver is thin
Born of the same parents' balloon sample becomes, or even with the different degrees of necrosis of liver cell；(3) inflammation is important in inflammatory cell infiltration, or leaflet in leaflet
Portal area.
Imaging diagnosis
Fatty live lesions degree is judged according to B ultrasound performance：(1) mild fatty liver：Luminous point is fine and closely woven, near field Echoenhance, far
Field echo is slightly decayed, and blood vessel structure is clear；(2) moderate fatty liver：Luminous point is fine and closely woven, front court Echoenhance, and far field decay is obvious,
Blood vessel structure is unintelligible；(3) severe fatty liver：Luminous point is fine and closely woven, and front court echo significantly increases, and far field echo is significantly decayed, blood vessel
Structure can not be recognized.
Fatty live lesions degree is judged according to CT performances：(1) it is slight：Liver density is reduced, CT values slightly less than spleen, and liver/
Spleen CT ratio≤1.0；(2) blood vessel shows unclear in liver/spleen CT ratio≤0.7, liver；(3) liver density, which to significantly reduce very cause, is in
Blood vessel is high-visible in negative value, liver/spleen CT ratio≤0.5, liver.
Research approach
80 patients are randomly divided into 2 groups, treatment group 50, control group 30.Treatment group man 40, female 10 is average
45.1 years old age, control group man 20, female 10, average age 43.6 years old.
Therapeutic scheme
Treatment group, patient takes the capsule of embodiment 1, and 3 times a day, once two grains, takes 8 weeks, while synkinesia is controlled
Treat, it is daily to run 2 kilometers, or swimming 0.3 hour or mountaineering.
Control group, gives placebo, synkinesia treatment is daily to run 2 kilometers, or swimming 0.3 hour or mountaineering.
Treatment phase notes tune dietary structure, and food rich in fat is eaten less.
Treatment results
Observe sign and biochemical indicator
Respectively in treatment stage the 0th, 8 weeks detection liver function (glutamic-pyruvic transaminase ALT, glutamic-oxalacetic transaminease AST, γ~paddy
Aminoacyl transferases GGT), blood fat (cholesterol TC, triglycerides TG) and iconography (CT or B ultrasound) check.
Curative effect determinate standard
Clinical symptoms curative effect determinate standard (《New Chinese medicine guideline of clinical investigations》)
(1) general curative effect criterion
1. fully recover：Symptom, sign disappear or basic disappearance, and symptom integral reduces >=95%；
2. it is effective：Symptom, sign are obviously improved, and symptom integral reduces by >=70%, but ＜ 95%；
3. it is effective：Symptom, sign take a turn for the better, and symptom integral reduces by >=30%, but ＜ 70%；
4. it is invalid：Symptom, sign are not improved, even aggravating, symptom integral reduces ＜ 30%.
Note：Integration × 100% before therapeutic index=(being integrated before treatment after integration~treatment)/treatment；
The treatment number of total effective rate=(clinical recovery+effective+effective number)/total.
Therapeutic effect see the table below 1.
The treatment results of table 1
| Packet | n | Recovery from illness | It is effective | Effectively | It is invalid | Total effective rate |
| Treatment group | 50 | 30 | 12 | 5 | 3 | 94% |
| Control group | 30 | 5 | 8 | 7 | 10 | 66.7% |
The clinical experimental study of upper table 1 shows that traditional Chinese medicine composition for treating non-alcoholic fatty liver curative effect of the invention is bright
It is aobvious, few side effects.
Claims (1)
1. a kind of Chinese medicine composition for treating NASH, by the chinese medicine material or their extract group of following weight
Into tinosporae 16g, golden cypress 15g, sweet wormwood 25g, stringy stonecrop 15g, Radix Astragali 26g and semen armeniacae amarae 8g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510147954.XA CN104666550B (en) | 2015-03-31 | 2015-03-31 | A kind of Chinese medicine composition for treating NASH |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510147954.XA CN104666550B (en) | 2015-03-31 | 2015-03-31 | A kind of Chinese medicine composition for treating NASH |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104666550A CN104666550A (en) | 2015-06-03 |
| CN104666550B true CN104666550B (en) | 2017-07-11 |
Family
ID=53302486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510147954.XA Expired - Fee Related CN104666550B (en) | 2015-03-31 | 2015-03-31 | A kind of Chinese medicine composition for treating NASH |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104666550B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201805057XA (en) * | 2015-12-25 | 2018-07-30 | Nippon Soda Co | Absorbent particles |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103877323A (en) * | 2014-03-07 | 2014-06-25 | 广东药学院 | Medicinal composition for treating non-alcoholic fatty liver disease |
-
2015
- 2015-03-31 CN CN201510147954.XA patent/CN104666550B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103877323A (en) * | 2014-03-07 | 2014-06-25 | 广东药学院 | Medicinal composition for treating non-alcoholic fatty liver disease |
Non-Patent Citations (1)
| Title |
|---|
| 清热解毒法与养阴活血法对NASH大鼠IL-1β、IL-18影响的实验研究;季巍巍等;《中华中医药学会第十五届内科肝胆病学术会议暨国际中医药管理局专科专病协作组（肝病组、传染病组）会议论文集》;20121031;第635-638页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104666550A (en) | 2015-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103301412A (en) | Traditional Chinese medicine composition for treating alcoholic liver | |
| CN103340341A (en) | Functional food with bone strengthening effect and preparation method thereof | |
| CN101797301B (en) | Medicine for preventing and curing middle and old aged constipation | |
| CN103301267B (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
| CN101496894A (en) | Medicament for treating fatty liver and preparation method thereof | |
| CN103223069A (en) | Traditional Chinese medicine composition for treating hepatitis | |
| CN104666550B (en) | A kind of Chinese medicine composition for treating NASH | |
| CN102847061B (en) | Traditional Chinese medicine preparation for treating pediatric viral myocarditis and preparation method thereof | |
| CN102641469B (en) | Medicinal composition for preventing or treating nonalcoholic steatohepatitis | |
| CN105560779A (en) | Non-alcoholic fatty liver disease prevention and control compound preparation and use thereof | |
| CN103330837B (en) | Traditional Chinese medicine composition for curing osteoporosis of menopausal women | |
| CN105106758A (en) | Traditional Chinese medicine composition for treating phlegm and blood stasis type dizziness | |
| CN105327115B (en) | A kind of prevention and treatment type II diabetes Phellinus is logical to rush down formula and preparation process | |
| CN103272146A (en) | Medicine composition used for preventing and treating alcoholic fatty liver and preparation method thereof | |
| CN104257839B (en) | A kind of Chinese medicine composition with hypoglycemic protection blood vessel endothelium effect and preparation method thereof | |
| CN102106992B (en) | Chinese medicinal granules for treating non-alcoholic steatohepatitis | |
| CN101375962B (en) | Formulation for activating blood and freeing collateral vessels and preparation method thereof | |
| CN113304235A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN103705868B (en) | One treats hyperthyroid pharmaceutical composition and application thereof | |
| CN104189757A (en) | Traditional Chinese medicine for treating alcoholic liver | |
| CN106420901B (en) | A kind of herbal mixture for treating fatty liver | |
| CN105362966A (en) | Method for preparing traditional Chinese medicine preparation for treating fatty liver | |
| CN115944700A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN104800573A (en) | Chinese medicinal composition for treating liver cancer and preparation method thereof | |
| CN104958596A (en) | Traditional Chinese medicine composition for hernia patient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170711 Termination date: 20180331 |